This study is for people with relapsing multiple sclerosis (RMS), a condition where the immune system attacks the protective covering of nerves. The study tests a medicine called ublituximab, which could help improve walking and reduce falls. Participants will have 48 weeks of treatment and be checked three times: before, halfway, and at the end.
During tests, participants will walk on a treadmill while safely harnessed, and their reactions to slips will be monitored. Researchers will also check their disability status and thinking skills to see how the medicine affects these areas. The goal is to understand if ublituximab can help improve walking and overall activity in people with RMS.
- Length of Study: 48 weeks.
- Visits Needed: Three main assessments.
- Risks: Potential side effects of ublituximab and reactions during treadmill tests.